Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imaging

Walter P Maksymowych, Rebecca Bolce, Gaia Gallo, Emily Seem, Vladimir J Geneus, David M Sandoval, Mikkel Østergaard, Kurisu Tada, Xenofon Baraliakos, Atul Deodhar, Lianne S Gensler, Walter P Maksymowych, Rebecca Bolce, Gaia Gallo, Emily Seem, Vladimir J Geneus, David M Sandoval, Mikkel Østergaard, Kurisu Tada, Xenofon Baraliakos, Atul Deodhar, Lianne S Gensler

Abstract

Objective: To evaluate response rates at week 16 with ixekizumab in patients with radiographic axial SpA (r-axSpA) and elevated or normal/low baseline inflammation measured by serum CRP or spinal MRI using data from two randomized, double-blind, placebo (PBO)-controlled phase III trials.

Methods: Biologic-naïve (COAST-V) or TNF inhibitor-experienced (COAST-W) adults with active r-axSpA received 80 mg ixekizumab every 2 weeks (IXEQ2W) or 4 weeks (IXEQ4W) or PBO or active reference [40 mg adalimumab every 2 weeks (ADAQ2W) in COAST-V. At week 16, patients receiving ixekizumab continued as assigned and patients receiving PBO or ADA were rerandomized 1:1 to IXEQ2W or IXEQ4W through week 52. Assessment of SpondyloArthritis international Society 40% (ASAS40) response rates were examined by baseline CRP (≤5 or >5 mg/l) and Spondyloarthritis Research Consortium of Canada (SPARCC) MRI spine inflammation score (<2 or ≥2).

Results: In the COAST-V/W integrated dataset (N = 567), significantly more patients treated with ixekizumab achieved ASAS40 response at week 16 by CRP ≤5 mg/l (27% IXEQ4W, P < 0.05; 35% IXEQ2W, P < 0.01 vs 12% PBO), CRP >5 mg/l (39% IXEQ4W, P < 0.001; 43% IXEQ2W, P < 0.001 vs 17% PBO), SPARCC MRI spine score <2 (40% IXEQ4W P < 0.01, 52% IXEQ2W P < 0.001 vs 16% PBO), and SPARCC MRI spine score ≥2 (44% IXEQ4W P < 0.001, 47% IXEQ2W P < 0.001 vs 19% PBO). ASAS40 response was observed with CRP ≤5 mg/l and SPARCC MRI spine score <2 with IXEQ4W (29%) and was significant with IXEQ2W (48%; P < 0.05) vs PBO (13%).

Conclusion: Ixekizumab demonstrated efficacy in the treatment of AS/r-axSpA in patients with and without elevated CRP or evidence of spinal inflammation on MRI.

Trial registration: ClinicalTrials.gov (https://ichgcp.net/clinical-trials-registry/NCT02696785" title="See in ClinicalTrials.gov">NCT02696785, NCT02696798.

Keywords: AS; CRP; MRI; inflammation; ixekizumab; randomized clinical trials.

© The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology.

Figures

Fig . 1
Fig. 1
ASAS40 response by baseline CRP and relationship based on a logistic regression model ASAS40 response at week 16 by baseline CRP ≤5 or >5 mg/L (A–F) and the relationship between ASAS40 response at week 16 and baseline CRP levels based on a logistic regression model for (G) COAST-V and (H) COAST-W. The analysis was performed on the full range of baseline values. Baseline values of 0–50 are shown. n: number of patients with ASAS40 response; Ns: number of patients in the subgroup; Nx: number of patients with non-missing values; ADA: active reference, adalimumab; ASAS40: 40% improvement in disease activity by ASAS criteria; IXE: ixekizumab; PBO: placebo. *P < 0.05, †P < 0.01, ‡P < 0.001 vs placebo.
Fig . 2
Fig. 2
ASAS40 response by baseline MRI inflammation ASAS40 response at week 16 by baseline SPARCC MRI spine score A, B, E–H) and baseline SPARCC MRI SI joint score <2 or ≥2 (C, D). n: number of patients with ASAS40 response; Ns: number of patients in the subgroup. *P < 0.05, †P < 0.01, ‡P < 0.001 vs placebo.
Fig . 3
Fig. 3
Relationship between ASAS40 response and baseline MRI inflammation based on a logistic regression model Relationship between ASAS40 response at week 16 and baseline SPARCC MRI spine score in (A) COAST-V and (C) COAST-W and (B) the relationship between ASAS40 response at week 16 and baseline SPARCC MRI SI joint score in COAST-V based on a logistic regression model. The analysis was performed on the full range of baseline values. Baseline values of 0–50 are shown. Nx: number of patients with non-missing values.
Fig . 4
Fig. 4
ASAS40 response by baseline CRP and MRI spine inflammation ASAS40 response at week 16 by (A) absence of inflammation as measured by baseline CRP ≤5 mg/L and SPARCC MRI spine score <2 and by (B) elevated inflammation as measured by baseline CRP >5 mg/l and/or SPARCC MRI spine score ≥2. n: number of patients with ASAS40 response; Ns: number of patients in the subgroup. *P < 0.05, ‡P < 0.001 vs placebo.

References

    1. Sieper J, Poddubnyy D.. Axial spondyloarthritis. Lancet 2017;390:73–84.
    1. Rudwaleit M, Khan MA, Sieper J.. The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? Arthritis Rheum 2005;52:1000–8.
    1. Ward MM, Deodhar A, Gensler LS. et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol 2019;71:1599–613.
    1. Dougados M, Baeten D.. Spondyloarthritis. Lancet 2011;377:2127–37.
    1. Stolwijk C, van Tubergen A, Castillo-Ortiz JD, Boonen A.. Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis 2015;74:65–73.
    1. Elewaut D, Matucci-Cerinic M.. Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice. Rheumatology (Oxford) 2009;48:1029–35.
    1. Braun J, Pham T, Sieper J. et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003;62:817–24.
    1. Braun J, Davis J, Dougados M. et al. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:316–20.
    1. Coates LC, Marzo-Ortega H, Bennett AN, Emery P.. Anti-TNF therapy in ankylosing spondylitis: insights for the clinician. Ther Adv Musculoskelet Dis 2010;2:37–43.
    1. Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J.. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 2004;63:665–70.
    1. Inman RD, Davis JC Jr, Heijde D. et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008;58:3402–12.
    1. de Vries MK, van Eijk IC, van der Horst-Bruinsma IE. et al. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. Arthritis Rheum 2009;61:1484–90.
    1. Vastesaeger N, van der Heijde D, Inman RD. et al. Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis 2011;70:973–81.
    1. Braun J, Baraliakos X, Hermann KG, Xu S, Hsu B.. Serum C-reactive protein levels demonstrate predictive value for radiographic and magnetic resonance imaging outcomes in patients with active ankylosing spondylitis treated with golimumab. J Rheumatol 2016;43:1704–12.
    1. Rudwaleit M, Schwarzlose S, Hilgert ES. et al. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis 2007;67:1276–81.
    1. Liu L, Lu J, Allan BW. et al. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res 2016;9:39–50.
    1. van der Heijde D, Cheng-Chung Wei J, Dougados M. et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet 2018;392:2441–51.
    1. Dougados M, Wei JC-C, Landewé R. et al. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). Ann Rheum Dis 2020;79:176–85.
    1. Deodhar A, Poddubnyy D, Pacheco-Tena C. et al. Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors. Arthritis Rheumatol 2019;71:599–611.
    1. Deodhar A, van der Heijde D, Gensler LS. et al. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. Lancet 2020;395:53–64.
    1. Sieper J, Rudwaleit M, Baraliakos X. et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 2009;68(Suppl 2):ii1–44.
    1. van der Linden S, Valkenburg HA, Cats A.. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361–8.
    1. Maksymowych WP, Inman RD, Salonen D. et al. Spondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of spinal inflammation in ankylosing spondylitis. Arthritis Rheum 2005;53:502–9.
    1. Maksymowych WP, Inman RD, Salonen D. et al. Spondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis. Arthritis Rheum 2005;53:703–9.
    1. Ginde AA, Foianini A, Renner DM, Valley M, Camargo CA Jr.. Availability and quality of computed tomography and magnetic resonance imaging equipment in U.S. emergency departments. Acad Emerg Med 2008;15:780–3.
    1. Gong Y, Zheng N, Chen SB. et al. Ten years’ experience with needle biopsy in the early diagnosis of sacroiliitis. Arthritis Rheum 2012;64:1399–406.
    1. Richter F, Natura G, Ebbinghaus M. et al. Interleukin-17 sensitizes joint nociceptors to mechanical stimuli and contributes to arthritic pain through neuronal interleukin-17 receptors in rodents. Arthritis Rheum 2012;64:4125–34.
    1. Baschant U, Frappart L, Rauchhaus U. et al. Glucocorticoid therapy of antigen-induced arthritis depends on the dimerized glucocorticoid receptor in T cells. Proc Natl Acad Sci USA 2011;108:19317–22.
    1. Weiß A, Song IH, Haibel H, Listing J, Sieper J.. Good correlation between changes in objective and subjective signs of inflammation in patients with short- but not long duration of axial spondyloarthritis treated with tumor necrosis factor-blockers. Arthritis Res Ther 2014;16:R35.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere